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Simple Summary: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both
sensitivity and specificity. Human circulating progastrin (hPG80 ) can be easily measured in plasma by
ELISA. This study is the first to examine hPG80 in NENs. The study demonstrated increased levels of
hPG80 in all sub-types of NENs, with a high sensitivity and specificity demonstrated. Plasma hPG80
in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study
is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG80 as a means of
monitoring disease (NCT04750954).
Abstract: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG80 ) is a novel biomarker that can be
easily measured in plasma by ELISA. This study is the first to examine hPG80 in NENs. Plasma
hPG80 was quantified from 95 stage IV NEN patients, using DxPG80 technology (ECS Progastrin,
Switzerland) and compared with hPG80 concentrations in two cohorts of healthy donor controls
aged 50–80 (n = 252) and 18–25 (n = 137). Median hPG80 in NENs patients was 5.54 pM compared to
1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort (p < 0.0001). Subgroup analysis revealed
median hPG80 levels significantly higher than for either control cohort in neuroendocrine carcinoma
(NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC)
sub-cohort (n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both
sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG80
in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study
is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG80 as a means of
monitoring disease (NCT04750954).
Keywords: circulating progastrin; hPG80 ; blood-based diagnostic biomarker; neuroendocrine neoplasms;
neuroendocrine tumors; neuroendocrine carcinoma; small-cell carcinoma

Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

1. Introduction
Neuroendocrine neoplasms (NENs) are heterogeneous tumors that originate from
various organs and are of variable aggressiveness based on grade and morphology. The
incidence of neuroendocrine tumors (NETs) has increased 6.4-fold, making NETs the second
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most prevalent gastrointestinal malignancies after colorectal cancer [1,2]. Currently, no
reliable blood-based biomarkers have been identified for NENs. Several biomarkers have
been proposed for well-differentiated NETs (e.g., chromogranin A and pancreastatin);
however, to date, all of the proposed biomarkers are not particularly sensitive and/or
specific [3].
Progastrin, a precursor of gastrin is synthetized by G cells in gastric antrum and
later processed into gastrin [4]. In normal physiologic state, progastrin esnt accumulate in
antral G cells, as compared to G34-Gly and fully matured gastrin [5]. Hence, progastrin
is not detectable in the blood in normal subjects, barring few exceptions. [6]. In contrast,
as a result of GAST gene expression, high hPG80 levels are detected in blood of cancer
patients [7–9]. GAST, a target of the ß-catenin/Tcf4 pathway, is also found to be activated
in many solid tumors [10]. Role of hPG80 in tumorigenesis has been well documented in
prior publications [9,11–14]. Therefore, we conducted a pilot study to test the presence of
hPG80 in neuroendocrine neoplasms.
2. Materials and Methods
2.1. Patients and Control Cohorts
Institutional Review Board (IRB) approval was secured and banked plasma from patients with high-grade neuroendocrine carcinoma and well-differentiated neuroendocrine
tumors was accessed from the University of Kentucky Markey Cancer Center’s biospecimen
repository.
Control group comprised of plasma samples from two distinct age groups. Plasma
from healthy, 137 non fasting (18–25-year-old) blood donors was obtained from the French
blood agency (Etablissement Français du Sang) [15]. A second cohort consisted of 50–80year-old; (median 55). Plasma from these 252 fasting subjects was obtained from PROCODE
study (NCT03775473, https://clinicaltrials.gov/ct2/show/NCT03775473, accessed on 17
December 2021).
2.2. hPG80 Level Measurements in the Blood Samples
hPG80 was analyzed using ELISA DxPG80 .lab kit from ECS-Progastrin. The analytical
performances of the kit are described in Cappellini et al. [16]. Limit of Detection (LoD)
and the limit of Quantitation (LoQ) is at 1 pM and 3.3 pM respectively. The inter- and
intra-assay coefficients of variation (CV%) is below 10%. No cross-reactivity was detected
with gastrin-17, Gastrin-Gly or CTFP (C-Terminus Flanking Peptide). No cross-reactivity
was detected with other blood biomarker such as CA125, CEA or PSA. No interference was
detected with chemicals such as SN-38, 5-FU or triglycerides, cholesterol, or hemoglobin.
2.3. Statistical Analysis
Differences in hPG80 levels were evaluated using Mann–Whitney U tests. The diagnostic discriminative accuracy of hPG80 levels in patients with cancer compared to healthy
subjects was assessed using Receiver Operating Characteristics (ROC) curve analysis. Both
control groups were used for ROC curve analysis in order to obtain a range of values
regarding the diagnosis value of hPG80 . Prism software (GraphPad Prism version 9.4 for
Windows, GraphPad Software, La Jolla, CA, USA, www.graphpad.com, accessed on 17
December 2021) was used to perform all the statistical analysis and to create figures. The
level of significance was set at p < 0.05.
3. Results
3.1. Diagnostic Performance of hPG80 in the Various Cohorts of Cancer Patients
The demographic characteristics of the neuroendocrine neoplasm (NEN) patients and
control cohorts are shown in Table 1.
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Table 1. Clinical and pathological characteristics for NEN, NEC, NET patients, and control cohorts.

Age (years)
Gender

hPG80

Stage

Median (range)

NEC

NET

N (%)

N (%)

N (%)

Control Cohorts
18–25 Years Old

50–80 Years Old

N (%)

N (%)

n = 95

n = 25

n = 70

n = 137

n = 252

61 (37–86)

61 (37–78)

62 (37–86)

21 (18–25)

55 (50–80)

Male

38 (40%)

10 (40%)

28 (40%)

79 (57.7%)

99 (39.3%)

Female

57 (60%)

15 (60%)

42 (60%)

58 (42.3%)

153 (60.7%)

Median (IQR), pM

5.54 (0.00–1241)

3.54 (1.13–154.1)

5.8 (0.00–1241)

<LoD

<LoQ

Mean (SD) pM

28.24 (128.8)

20.7 (39.96)

30.55 (148.5)

<LoD

3.82 (0.55)

I to III

14 (14.8%)

2 (8%)

12 (17.2%)

IV

80 (84.2%)

23 (92%)

57 (81.4%)

Unknown

1 (1.0%)

0 (0%)

1 (1.4%)

1

2
Grade
3

Unknown

GI tract

Pancreas

Primary Site

NEN

SCLC
Lung w/o SCLC

Other

33

0

33

(34.7%)

(0%)

(47.2%)

28

0

28

(29.5%)

(0%)

(40%)

30

25

5

(31.6%)

(100%)

(7.1%)

4

0

4

(4.2%)

(0%)

(5.7%)

46

4

42

(48.4%)

(16%)

(60%)

15

2

13

(15.8%)

(8%)

(18.6%)

13

13

0

(13.7%)

(52%)

(0%)

17

4

13

(17.9%)

(16%)

(18.6%)

4

2

2

(4.2%)

(8%)

(2.8%)

NA

NA: not applicable; LoD: Limit of Detection; LoQ: Limit of Quantification.

The median age of NEN patients was 61 years (37–86 y). Among the 95 NENs,
25 patients (26.3%) had high-grade neuroendocrine carcinoma (NEC) and 70 patients
(73.7%) were diagnosed with well-differentiated neuroendocrine tumors (NET). The median hPG80 in NENs patients was 5.54 pM (IQR 2.07–17.11 pM) as compared to 1.5 pM
(IQR 0.60–3.09 pM) for patients in the 50–80-year-old control group and 0.29 pM (IQR
0.00–1.27 pM) for patients in the 18–25-year-old cohort (p < 0.0001, two-tailed Mann–
Whitney U-test). A subgroup analysis of NENs revealed a median hPG80 of 3.54 pM (IQR
2.02–19.91 pM) in neuroendocrine carcinoma (NEC n = 25) and 5.8 pM (IQR 1.91–16.74 pM)
in neuroendocrine tumor (NET n = 70). Interestingly, the small-cell lung cancer subcohort (n = 13) also showed significant elevation of hPG80 with a median at 9.09 pM (IQR
2.66–25.33 pM). All the above-mentioned differences were statistically significant as compared to healthy controls (Figure 1). Table 2 shows the levels of plasma hPG80 in the various
study subgroups.

Cancers 2022, 14, x FOR PEER REVIEW

Cancers 2022, 14, 863

4 of 9

4 of 8
healthy controls (Figure 1). Table 2 shows the levels of plasma hPG80 in the various study
subgroups.

Figure1.1.Diagnostic
Diagnosticperformance
performanceofofhPG
hPG8080inin
(A)
NENs,NEC
NECand
andNET
NETpatient
patientcohorts,
cohorts,(B)
(B)bybytumor
tumor
Figure
(A)
NENs,
grade,(C)
(C)by
bytumor
tumorsite
siteasascompared
comparedtotothe
the18–25-year-old
18–25-year-oldand
and50–80-year-old.
50–80-year-old.
grade,

Table
plasmafrom
fromneuroendocrine
neuroendocrineneoplasm
neoplasmpatients
patients
depending
grade
Table2.2.hPG80
hPG80 (pM) in plasma
depending
onon
thethe
grade
and
and
the
primary
site.
Groups
are
not
significantly
different
from
each
other.
the primary site. Groups are not significantly different from each other.

Grade I

hPG80

Median
(range), pM
Mean (SD),
pM

Median
(range), pM
8.66 (0.00–1241)
hPG80
Mean (SD),
pM
48.71 (214.4)

GRADE
Grade II

GRADE

Grade I

Grade II

Grade III

Grade III

8.66 (0.00–1241)

5.3 (0.00–142.1)

4.22 (1.13–154.1)

48.71 (214.4)

16.37 (32.1)

19.18 (36.77)

5.3 (0.00–142.1)
16.37 (32.1)

4.22 (1.13–154.1)
19.18 (36.77)

PRIMARY SITE

PRIMARY SITE

GI Tract

hPG80

Median
(range), pM
Mean (SD),
pM

GI Tract
Pancreas

6.06
6.06 (0.00–
Median4.14 (0.00–1241)
(0.00–142.1)

(range), pM
142.1)
Mean (SD),88.9 (318.9)
13.88 (24.02)
(24.02)
pM

hPG80
13.88

Lung not
SCLC
Lung not SCLC
SCLC
9.09
4.14 (0.00–
9.09 (1.35–
4.51 (0.00–
4.51 (0.00–34.85)
(1.35–124.1)
1241)
124.1)
34.85)
Pancreas
SCLC

30.36

Other
Other
16.8916.89
(1.13–
(1.13–86.87)
86.87)
30.45

11.37 (11.35)
88.9 (318.9)
(39.78)
(52.78) 30.36 (52.78) 11.37 (11.35) 30.45(39.78)

hPG80 : circulating progastrin; IQR: interquartile range; pM: picomolar; SD: standard deviation; GI: gastrointestinal;
hPG
80: circulating progastrin; IQR: interquartile range; pM: picomolar; SD: standard deviation; GI:
SCLC: small-cell lung cancer.
gastrointestinal; SCLC: small-cell lung cancer.

3.2. Diagnostic Performance of hPG in Each Sub-Cohort of Cancer Type
3.2. Diagnostic Performance of hPG8080in Each Sub-Cohort of Cancer Type
As shown in Figure 2, diagnostic accuracy, estimated by the ROC AUCs, is 0.89 for
As shown in Figure 2, diagnostic accuracy, estimated by the ROC AUCs, is 0.89 for
all NENs, 0.87 for NETs, and 0.92 for NECs when compared to the young 18–25 y control
all NENs, 0.87 for NETs, and 0.92 for NECs when compared to the young 18–25 y control
group; for the older 50–80 y cohort, the values were 0.75 for all NENs, 0.74 for NETs, and
group; for the older 50–80 y cohort, the values were 0.75 for all NENs, 0.74 for NETs, and
0.75 for NECs.
0.75 for NECs.
As shown in Figure 3, diagnostic performances of hPG80 were tested using 90%
specificity (CI: 89.8% to 93.4% for the 18–25-year-old and 84.4% to 93.3% for the 50–80-yearold control groups) for all sub-cohorts. The sensitivity ranged from 58.67% (CI: 40.74%
to 74.49%) for lung other than SCLC to 69.23% (CI: 42.37% to 87.32%) for SCLC, when
compared to the 18–25 y control group. The sensitivity ranged from 37.50% (CI: 21.16% to
57.29%) for NEC to 53.85% (CI: 29.14% to 76.79%) for SCLC, when compared to the 50–80 y
control group.
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Figure 2. Diagnostic accuracy, estimated by the Receiver Operator Characteristic (ROC) Area Under
the Curve (AUC)s, is 0.89 for all NENs (A), 0.92 for NECs (B), and 0.87 for NETs (C) when compared
to the young 18–25 y control group (square); for the older 50–80 y cohort, the values were 0.75 for
all NENs (A), 0.75 for NECs (B), and 0.74 for NETs (C) (triangles).

As shown in Figure 3, diagnostic performances of hPG80 were tested using 90% specificity (CI: 89.8% to 93.4% for the 18–25-year-old and 84.4% to 93.3% for the 50–80-yearold control groups) for all sub-cohorts. The sensitivity ranged from 58.67% (CI: 40.74% to
74.49%)
for lung other
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As shown in Figure 3, diagnostic performances of hPG80 were tested using 90% specificity (CI: 89.8% to 93.4% for the 18–25-year-old and 84.4% to 93.3% for the 50–80-yearold control groups) for all sub-cohorts. The sensitivity ranged from 58.67% (CI: 40.74% to
74.49%) for lung other than SCLC to 69.23% (CI: 42.37% to 87.32%) for SCLC, when compared to the 18–25 y control group. The sensitivity ranged from 37.50% (CI: 21.16% to
57.29%) for NEC to 53.85% (CI: 29.14% to 76.79%) for SCLC, when compared to the 50–80
y control group.
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control group
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50–80 yy control
controlgroup.
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set at 90% as compared to (A) 18–25

4. Discussion
Neuroendocrine neoplasms represent a group of diseases with a common neuroendocrine lineage however each subgroup maintains its unique morphology, molecular
biology, and phenotype. WHO now clearly distinguishes poorly differentiated neuroendocrine carcinoma aka NEC from well differentiated neuroendocrine tumor, also known
as
NET.
NEC is characterized
by an aggressive
clinicalneoplasm)
course, is
distinctively
poorly
Figure
3. Sensitivity
of hPG80 in the all-patient
(neuroendocrine
cohorts
with a specificity
differentiated,
displays
large
cell
or
small
cell
morphology,
and
has
a
molecular
profile
set at 90% as compared to (A) 18–25 y control group and (B) 50–80 y control group.
indicative of mutation in TP53 and loss of RB1. In contrast, the well differentiated NETs are
relatively indolent and can be differentiated into grade 1, 2, and 3 based on Ki 67 index.
It is critical to distinguish between NET and NEC as both can have a variable clinical
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course and management paradigms [17]. However, a common unifying factor for both NET
and NEC is lack of reliable blood-based diagnostic biomarker. hPG80 (human circulating
progastrin) is a pan tumor biomarker that has been found to be over-expressed in multiple
malignancies. hPG80 synthesis is product of overexpression of GAST gene in cancer cells
and human circulating progastrin can now be measured accurately with help of DxPG80
Enzyme-Linked Immunosorbent Assay (ELISA) based test [8,16].
In this study, we investigated the diagnostic value of plasma hPG80 in patients with
both low- and high-grade NENs. Our data revealed that plasma hPG80 levels in 95 patients with NENs was significantly higher compared to healthy blood donors. NENs are
a heterogenous group of diseases that can arise from any location in the body [18]. Because of its broad expression in all types of NENs, plasma hPG80 could represent a novel
biomarker to diagnose NENs. In fact, except chromogranin A (CgA), which is secreted
by most NENs, currently-used biomarkers (neuron-specific enolase, pancreatic peptide
and 5-hydroxyindoleacetic acid) have restricted expression, thus limiting their diagnostic
value [19]. We showed that hPG80 diagnostic sensitivity ranged from 58.67% to 69.23%
with a 90% specificity in NENs. Only few biomarkers including CgA are currently used in
the diagnosis of patients with NENs [20]. Although these biomarkers are considered useful
to aid diagnosis, they display limited sensitivity and specificity. Indeed, the sensitivity
and specificity of CgA ranges between 43 and 100%, and below 50%, respectively [3]. In
addition, elevated CgA levels are also found in many other conditions such as renal and
hepatic failure, inflammatory diseases, or following the use of proton-pump inhibitors [21].
Another limitation to the use of CgA for NENs diagnosis comes from the absence of direct
involvement in the mechanisms that underlie tumorigenic process including cell proliferation, migration, invasion, and metastasis [22]. By contrast, numerous studies have
demonstrated that hPG80 contribute to tumorigenesis and tumor development [9,11–13].
Plasma hPG80 levels correlate with tumor burden but also with tumor activity. Indeed,
hPG80 level significantly decreases upon surgery in peritoneal carinomatosis and upon
remission in hepatocellular cancer [8]. In addition, in hepatocellular cancer, the hPG80 level
correlates with response to treatment and disease progression [8]. Last but not least, we
have recently shown that hPG80 could be used for prognosticating survival in metastatic
renal cell carcinoma [7]. In line with these data and to gain further insight into its potential
utility as a biomarker in NENs, the role of hPG80 in disease monitoring is being studied
in an NCI (National Cancer Institute) sponsored multi center NET clinical trial (ETCTN
10450). Plasma hPG80 will be serially collected at baseline, at each radiographic (CT/MRI)
assessment, and at the time of progression.
Recently, the NETest, a blood-derived multianalyte test that measures the expression
of 51 circulating mRNA in blood, has been shown to outperform CgA in the diagnosis of
NENs [23]. NETest diagnostic accuracy, sensitivity, and specificity, were 97, 99, and 95%,
respectively [23]. However widespread use of this biomarker may be limited [24].
Due to the rarity of NECs, most of the molecular studies have focused on NETs. They
demonstrated that signaling pathways such as PI3K-Akt, Ras/Raf/MEK/ERK, Notch,
and Wnt/β-catenin signaling contribute to NET pathogenesis [10]. The Wnt-signaling
pathway is essential to regulate cell proliferation, migration during embryogenesis, and
tumorigenesis in various cancers [25]. Gene mutations in well-known components of
the Wnt-signaling pathways, such as β-catenin and APC, and repression of Wnt inhibitor
genes by DNA methylation or histone modification of their promoters (SFRP-1, Axin-2,
DKK-1, DKK-3, and WIF-1) are frequently observed in NET cell lines and human NET
tumor samples [10]. In addition, analysis of somatic mutations across 21 types of NETs
revealed that the gene MEN1, encoding a negative regulator of β-catenin, was the most
commonly mutated gene in NETs (8 out of 21 NET types) [26,27]. Remarkably the gene
GAST, encoding progastrin, is a direct target of the Wnt oncogenic pathway [28]. Therefore,
we can hypothesize that abnormal expression of the Wnt signaling pathway in NENs could
be linked to the overexpression of hPG80 in these tumors.
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Our study presents some limitations starting with the retrospective nature of the
study and the low patient number, especially in the different subgroups analyzed. Second,
most of the patients (84%) have advanced disease (stage IV), not allowing for evaluation
of the diagnostic value of hPG80 in early-stage patients. Lastly, the current study does
not account for potential confounders like use of proton-pump inhibitors, or fasting vs.
post-prandial state. We acknowledge that PPI usage could induce gastrin hyper secretion
(hypergastrinemia); however, to our knowledge, there is no publication showing an increase
in hPG80 during PPI usage. Furthermore, as described in Cappellini [16], we would like
to mention that the kit (DxPG80 ) that was used to measure hPG80 (human circulating
progastrin) does not recognize any other forms of gastrin peptides, avoiding any risk of
false positivity due to PPI usage and hypergastrinemia. Nonetheless, we are currently
setting up a clinical study to answer this very question. Finally, a large prospective study,
including more cases with early-stage disease, should strengthens the significance of using
hPG80 as a new diagnostic biomarker in NENs.
5. Conclusions
This first-ever study of plasma hPG80 in NENs confirms that hPG80 is elevated in both
low- and high-grade NENs, and suggests that hPG80 could be considered as a potential
diagnostic blood-based biomarker for NENs diagnosis.
Author Contributions: A.C.: conceptualization, methodology, investigation, data curation, data
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